Estimated wasteful spending on aducanumab dispensing in the U.S. Medicare population: A cross-sectional analysis.
作者信息
Oronce Carlos Irwin A, Arbanas Julia Cave, Leng Mei, Landon Bruce E, Damberg Cheryl L, Sarkisian Catherine, Mafi John N
机构信息
Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, California, Los Angeles, USA.
Department of Medicine, VA Greater Los Angeles Healthcare System, California, Los Angeles, USA.
出版信息
J Am Geriatr Soc. 2022 Sep;70(9):2714-2718. doi: 10.1111/jgs.17891. Epub 2022 Jun 27.
Abstract
摘要
相似文献
1
Estimated wasteful spending on aducanumab dispensing in the U.S. Medicare population: A cross-sectional analysis.美国医疗保险人群中阿杜卡单抗配药的估计浪费性支出：一项横断面分析。
J Am Geriatr Soc. 2022 Sep;70(9):2714-2718. doi: 10.1111/jgs.17891. Epub 2022 Jun 27.
2
Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?美国医疗保险和医疗补助服务中心（CMS）会在阿杜卡努单抗获得美国食品药品监督管理局（FDA）批准后，认定其对阿尔茨海默病的治疗合理且必要吗？
JAMA. 2021 Aug 3;326(5):383-384. doi: 10.1001/jama.2021.11768.
3
Estimated Annual Spending on Aducanumab in the US Medicare Program.美国医疗保险计划中阿杜卡奴单抗的预估年度支出。
JAMA Health Forum. 2022 Jan 14;3(1):e214495. doi: 10.1001/jamahealthforum.2021.4495. eCollection 2022 Jan.
4
Trends in Low-Value Health Service Use and Spending in the US Medicare Fee-for-Service Program, 2014-2018.2014 - 2018年美国医疗保险按服务收费计划中低价值医疗服务使用及支出趋势
JAMA Netw Open. 2021 Feb 1;4(2):e2037328. doi: 10.1001/jamanetworkopen.2020.37328.
5
Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication.阿特珠单抗用于撤回的加速批准适应证的医疗保险支出。
JAMA Oncol. 2021 Nov 1;7(11):1720-1721. doi: 10.1001/jamaoncol.2021.4757.
6
Geographic Variation in Medicare Fee-for-Service Health Care Expenditures Before and After the Passage of the Affordable Care Act.平价医疗法案通过前后医疗保险按服务收费的医疗保健支出的地域差异。
JAMA Health Forum. 2021 Dec 10;2(12):e214122. doi: 10.1001/jamahealthforum.2021.4122. eCollection 2021 Dec.
7
An approach to forecasting health expenditures, with application to the U.S. Medicare system.一种预测医疗支出的方法及其在美国医疗保险系统中的应用。
Health Serv Res. 2002 Oct;37(5):1365-86. doi: 10.1111/1475-6773.01112.
8
Medicare Coverage of Aducanumab - Implications for State Budgets.阿杜卡奴单抗的医疗保险覆盖范围——对州预算的影响。
N Engl J Med. 2021 Nov 25;385(22):2019-2021. doi: 10.1056/NEJMp2115297. Epub 2021 Nov 20.
9
Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.医疗保险不应涵盖阿杜卡奴单抗作为阿尔茨海默病的治疗手段。
Ann Neurol. 2021 Sep;90(3):331-333. doi: 10.1002/ana.26167. Epub 2021 Aug 10.
10
Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (AduhelmTM) to Patients Participating in Clinical Trials.公共政策应促进阿尔茨海默病治疗药物的可及性：对美国医疗保险将阿杜卡奴单抗（AduhelmTM）支付限制在参与临床试验患者的决定草案的评论。
J Prev Alzheimers Dis. 2022;9(2):241-246. doi: 10.14283/jpad.2022.25.
引用本文的文献
1
Reducing Wasteful Spending on Discarded Lecanemab in the US Medicare Program.减少美国医疗保险计划中在废弃的莱卡奈单抗上的浪费性支出。
JAMA Intern Med. 2024 Dec 1;184(12):1477-1479. doi: 10.1001/jamainternmed.2024.5292.
本文引用的文献
1
Estimated Annual Spending on Aducanumab in the US Medicare Program.美国医疗保险计划中阿杜卡奴单抗的预估年度支出。
JAMA Health Forum. 2022 Jan 14;3(1):e214495. doi: 10.1001/jamahealthforum.2021.4495. eCollection 2022 Jan.
2
Alzheimer's disease drug development pipeline: 2021.2021年阿尔茨海默病药物研发进展
Alzheimers Dement (N Y). 2021 May 25;7(1):e12179. doi: 10.1002/trc2.12179. eCollection 2021.
3
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.氟代硼吡咯 F 18 淀粉样蛋白正电子发射断层扫描与 36 个月认知功能衰退：一项前瞻性多中心研究。
Mol Psychiatry. 2014 Sep;19(9):1044-51. doi: 10.1038/mp.2014.9. Epub 2014 Mar 11.
4
National estimates of the quantity and cost of informal caregiving for the elderly with dementia.对老年痴呆症患者非正式照料的数量和成本的全国性估计。
J Gen Intern Med. 2001 Nov;16(11):770-8. doi: 10.1111/j.1525-1497.2001.10123.x.
Zotero 插件